Abstract. Aspirin (acetylsalicylic acid) is a well-known nonsteroidal anti-inflammatory drug that can potentiate some acute allergies and causes adverse immunological reactions collectively referred to as aspirin intolerance, a disorder that induces urticaria, asthma, and anaphylaxis in response to oral administration of the drug. Aspirin also potentiates some acute allergies such as food-dependent exercise-induced anaphylaxis (FDEIA), a food allergy induced by physical exercise. The anti-inflammatory actions as well as the adverse immunological effects have been thought to be primarily due to inhibition of cyclooxygenase activity. However, a growing body of evidence suggests that mechanisms unrelated to inhibition of prostaglandin synthesis are involved. One key feature of aspirin intolerance is the overproductions of cysteinyl leukotrienes (LTs), in which mast cells have been implicated to play a role. In this review, we provide an overview of our current knowledge about the regulatory mechanisms of LTC 4 secretion in mast cells and its modulation by aspirin, with a special emphasis on the role of Ca 2+ signals. We also introduced our recent findings that mast cells express dihydropyridine-sensitive L-type Ca 2+ channels (LTCCs) and that Ca 2+ channels of this kind mediate aspirin modulation of LTC 4 secretion in mast cells.
Introduction
Aspirin (acetylsalicylic acid, ASA) is a well-known nonsteroidal anti-inflammatory drug (NSAID) that can potentiate some acute allergies and causes adverse immunological reactions collectively referred to as aspirin intolerance. ASA intolerance is a disorder that induces urticaria, asthma, and anaphylaxis in response to oral administration of the drug (1, 2) . ASA also potentiates some acute allergies such as food-dependent exercise-induced anaphylaxis (FDEIA), a food allergy induced by physical exercise. Recently, ASA was shown to act as a powerful trigger of anaphylaxis in FDEIA patients (3) . The anti-inflammatory actions of ASA have been attributed primarily to inhibition of prostaglandin synthesis (4) . ASA acetylates Ser-530 of cyclooxygenase (COX) I and II, thereby blocking prostaglandin and thromboxane A 2 synthesis, while therapeutic concentrations of ASA and salicylates (SA) inhibit COX II protein expression (5) . An emerging view is that additional mechanisms, independent of COX inhibition, are involved in the anti-inflammatory actions of ASA and SA. These mechanisms include inhibiting the activity of the transcription factors nuclear factor κB (NF-κB) (6) and nuclear factor of activated T cells (NF-AT) (7) , as well as inhibiting degranulation of basophils and mast cells (8) .
One key feature of ASA intolerance is the overproduction of cysteinyl leukotrienes (cys-LTs) such as LTC 4 /D 4 /E 4 , which are all sequentially synthesized from arachidonic acid (AA). The cys-LTs are potent proinflammatory mediators and cause smooth muscle contraction and increased vascular permeability. Patients with ASA intolerance have significantly higher levels of cys-LTs in their bronchoalveolar lavage fluid and urine before and after oral ASA challenge (9) .
Mast cells are important effector cells in allergic and inflammatory reactions and are the major producers of cys-LTs. Mast cells express the high-affinity IgE receptor (FcεRI) on their cell surface, and antigen crosslinking of FcεRI triggers biochemical cascades that lead to degranulation, cys-LTs and PGs secretion, and cytokine production. Moreover, mast cells are suggested to be responsible for cys-LT overproduction in ASA intolerance (10, 11) . In addition, several studies have shown that an atopic background (high levels of serum IgE) is a risk factor for NSAID sensitivity (12) .
Dual effects of ASA and SA on IgE + Ag-mediated LTC 4 secretion in mast cells
We analyzed the effects of ASA on IgE + antigen (Ag)-mediated LTC 4 secretion and on the signaling pathways involved in secretion in cultured mast cells including RBL-2H3 cells and murine bone marrowderived mast cells (BMMCs) (13) . Cells that had been passively sensitized with anti-TNP IgE were treated with ASA and then immediately stimulated with the Ag TNP-BSA (the basal LTC 4 level, 48 ± 11 pg / ml; IgE + Ag stimulation, 3601 ± 218 pg/ ml, n = 5). Mortaz et al. (8) have reported that 10 mM ASA alone increases LT release, whereas ASA inhibits IgE + Ag-medated β-hexosaminidase release. In both cell types, however, 10 mM ASA exhibited substantial cytotoxicity, and ASA up to 3 mM had a no effect on LT release. ASA had a dual effect on IgE + Ag-mediated LTC 4 secretion, depending on the concentration employed: at low concentrations (≤ 0.3 mM), ASA significantly enhanced LTC 4 secretion, while at high concentrations (>1 mM), it suppressed secretion (Fig. 1A) . The optimal concentration of ASA was 0.1 -0.3 mM in different experiments (approximately 1.5-fold greater secretion compared to IgE + Ag stimulation alone). Similar results were obtained when cells were exposed to the aspirin metabolite SA: at low concentrations (≤0.3 mM), SA significantly enhanced IgE + Ag-mediated LTC 4 secretion, while at high concentrations (>1 mM), it suppressed secretion (Fig. 1B) . Essentially similar results were obtained with BMMCs (13) . SA was approximately 3-fold more toxic than ASA. Treatment with ASA up to 3 mM for 4 h had a minimal effect on cell viability, as measured by phosphatidylserine externalization and propidium iodide permeability or trypan blue dye exclusion assay (data not shown). DMSO in 3 mM ASA (0.3%) had minimal effects on secretion and viability (97%). These results demonstrate that ASA and SA exhibit stimulatory effects on IgE + Ag-mediated LTC 4 secretion at non-toxic concentrations. Since ASA suppresses COX-1 and COX-2 activities and SA does not (14) , these results suggest that the enhancement of LTC 4 secretion is not via suppression of COX activity.
ASA enhances cPLA 2 activation independently of the ERK and p38MAPK pathways To gain insight into the mechanisms by which ASA modulates LTC 4 secretion in mast cells, we examined the effect of ASA on the intracellular signaling pathways involved in LTC 4 synthesis, including activation of cytosolic phospholipase A 2 (cPLA 2 ), which mediates agonist-induced AA release in most cell types (15) . The catalytic activity of cPLA 2 is phosphorylationdependent. Phosphorylation of cPLA 2 on Ser-505 by ERK1/2 is necessary for cPLA 2 -mediated AA release following stimulation of various cell types by many different agonists (16, 17) . By using a monoclonal antibody that specifically recognizes the Ser-505 phosphorylation of cPLA 2 , we found that IgE + Ag stimulation substantially induced cPLA 2 phosphorylation, and that low concentrations (≤0.3 mM) of ASA substantially (1.5-fold) enhanced the effect ( Fig. 2A) . Thus, ASA enhanced both of IgE + Ag-mediated LTC 4 secretion and Ser-505 phosphorylation of cPLA 2 . We next examined whether ASA stimulated activation of ERK1/2. ERK1 /2 is activated following dual phosphorylation of a threonine and a tyrosine residue by the upstream kinase MEK1/2. RBL-2H3 cells were treated with various concentrations (0.1 -3 mM) of ASA prior to IgE + Ag stimulation, and activation of ERK1/ 2 was then assessed using a monoclonal antibody that specifically recognizes the dually phosphorylated (active) ERK1/2 (Thr 202 / Tyr 204 ) (18) . The phosphorylation of p42/44 ERK1/2 clearly increased following IgE + Ag stimulation (Fig. 2B) . However, ASA treatment dose-dependently reduced the activation of ERK1/2 (Fig. 2B) . The cPLA 2 Ser-727 residue is another site important for activation of the enzyme and is phosphorylated by MNK1-related protein kinases, which are activated by p38MAPK (19) . We therefore examined the effect of ASA on p38MAPK activation. Western blot analysis using a monoclonal antibody recognizing the active enzyme, phosphop38MAPK (Thr180/Tyr182), showed that IgE + Ag stimulation induced p38MAPK activation, but ASA at concentrations ranging from 0.1 to 3 mM did not substantially affect the phosphorylation level (Fig. 2C) . To determine the involvement of these MAPKs in LTC 4 secretion in our cell system, the effect of pharmacological inhibitors of selective MAPK pathways on IgE + Ag-mediated LTC 4 secretion was examined. U0126 (20 μM) and SB203580 (30 μM), which are selective inhibitors of ERK1/2 and p38MAPK, respectively, substantially (up to 50% inhibition) inhibited IgE + Agmediated LTC 4 secretion in RBL-2H3 cells, indicating that both MAPK pathways are involved in LTC 4 synthesis in our cell system. Collectively, our data indicate that ASA enhances cPLA 2 activation independently of the ERK and p38MAPK pathways.
IgE + Ag-mediated LTC 4 secretion is Ca
2+ -dependent and ASA has a dual effect on Ca 2+ responses
Another key physiological regulator of LTC 4 synthesis is Ca
2+
. cPLA 2 is regulated by an increase in intracellular Ca
, which binds to the amino-terminal C2 domain and induces cPLA 2 translocation to the nuclear envelope and the endoplasmic reticulum (20) . Ca 2+ is an important regulator of 5-lipoxygenase (5-LOX) as well, which catalyzes the addition of molecular oxygen to AA. Because Ca 2+ entry from the extracellular space is a major source of increased [Ca 2+ ] i , we determined whether LTC 4 secretion in mast cells was dependent on Ca 2+ influx. As shown in Fig. 3A , EGTA chelation of extracellular Ca 2+ completely abolished IgE-mediated LTC 4 secretion, indicating that this response is strictly dependent on Ca 2+ influx. We then examined the effect of ASA on Ca 2+ mobilization. ASA alone at concentrations ranging from 0.1 to 3 mM caused a minimal ] i increase (Fig. 3B) . Next, the effect of ASA on Ca 2+ mobilization from intracellular stores was examined in cells placed in nominally Ca 2+ -free medium. As shown in Fig. 3C ] i rise was seen following readmission of external Ca 2+ to the Tg-treated cells (Fig. 3D ). This Ca 2+ influx was almost completely abolished by 2-APB, a SOCE antagonist, indicating that the influx is SOC mediated. ASA (≥0.3 mM) suppressed Ca 2+ influx in a dosedependent manner. These results suggest that ASA may stimulate some other Ca 2+ -entry pathway.
ASA enhances LTC 4 secretion through facilitating LTCCs
Recent work has demonstrated that in various immune cells including T and B cells, in addition to SOCE, Ag-receptor stimulation can activate Ca 2+ entry independently of Ca 2+ store emptying. Moreover, we previously reported that IgE + Ag stimulation induces substantial Ca 2+ entry even when SOCE is inactive. In addition, this Ca 2+ entry was blocked by LTCC antagonists, but minimally affected by SOCE antagonists (24), suggesting the occurrence of LTCCs. More recently, we detected the expression of the LTCC α 1c (Ca v 1.2) transcripts and protein on mast cell surfaces. Inhibition of the LTCC activity by pharmacological antagonists such as nifedipine and diltiazem as well as small interfering RNA knockdown of α 1c (Ca v 1.2) LTCCs blocks IgE + Ag-mediated interleukin-13 and tumor necrosis factor-α productions, but not degranulation (25) . These findings suggest that mast cells express functional LTCCs, which are activated to regulate mediator secretion upon IgE + Ag stimulation. Therefore, we examined whether ASA might target this kind of Ca 2+ channels. Consistent with our previous studies (24, 25) indicating that it was due to entry of extracellular Ca 2+ (Fig. 4A ). This Ca 2+ entry was substantially reduced by the LTCC antagonist nifedipine but minimally affected by 2-APB. On the other hand, 2-APB completely abolished Ca 2+ influx through SOCs, while nifedipine enhanced it (Fig. 4 : B and C). ASA had a dual effect on this LTCC channel activity: at low concentrations (≤0.3 mM), ASA enhanced it, while at high concentrations (>1 mM), suppressed it (Fig. 4D ). These results demonstrate that ASA enhances DHP-sensitive LTCCs.
Next, we determined whether the DHP-sensitive LTCCs were involved in LTC 4 secretion. Tg could induce substantial LTC 4 secretion under normal conditions: 1 μM Tg was more effective than IgE + Ag stimulation with the optimal Ag concentration (Fig. 5A) . Depletion of intracellular Ca 2+ stores by Tg resulted in increased LTC 4 secretion, which may result from activation of SOCE (2689 ± 261 pg/ml, n = 6). In accordance with its inability to evoke the Ca 2+ response, Tg no longer induced any significant increase in LTC 4 secretion in the cells (3142 ± 318 pg/ml, Fig. 5B ). In contrast, IgE + Ag stimulation still significantly increased LTC 4 secretion (4520 ± 289 pg/ml), in parallel with substantial Ca 2+ entry. Moreover, ASA had a dual effect on the LTC 4 secretion: at low concentrations (0.3 mM), ASA significantly enhanced secretion (6311 ± 350 pg/ml, n = 4), while a high concentration (3 mM) suppressed secretion (3303 ± 484 pg/ml, n = 4, Fig. 5B ). Taken together, these findings suggest that ASA modulates IgE + Agmediated LTC 4 secretion through affecting the LTCC channel activity.
Concluding remarks
It has been demonstrated that Ca 2+ influx through CRAC channels regulates ERK activation, thereby controlling cPLA 2 activation and LTC 4 secretion (22, 23) . We demonstrated here the occurrence of another Ca
2+
-dependent pathway that leads to cPLA 2 activation and LTC 4 secretion independently of ERK activation. This pathway is mediated by DHP-sensitive LTCCs, which are pharmacologically distinct from SOCs (Fig. 6) . Furthermore, it was demonstrated that ASA modulates LTC 4 secretion through this LTCC-mediated pathway. Although the biological significance of these findings remained to be elucidated, it is noteworthy that the LTCC-mediated LTC 4 secretion is enhanced by mitochondrial depolarization, while the SOC-mediated LTC 4 secretion is blocked (13) . In the inflammatory milieu, mast cells may be exposed to oxidative stress, the major cause of mitochondrial depolarization, leading to inactivation of the SOC-mediated LTC 4 secretion. However, in the presence of ASA (especially at low doses), mast cells may produce substantially LTC 4 secretion through the LTCC pathway, leading to the exacerbation of IgE-mediated allergic reactions. Better understanding of the molecular mechanisms underlying ASA /SA modulation of LTCCs could lead to a new approach for the treatment of ASA-induced allergic and inflammatory disorders such as ASA intolerance and FDEIA. ]i increase in concert with ERK1 / 2 and / or p38MAPK activation cause increased LTC4 synthesis via cPLA2 activation. This SOC-mediated LTC4 synthesis is strictly dependent on mitochondrial polarization, probably because SOC activation requires normal mitochondrial functions. Our recent studies (24, 25) 
